US 12,071,436 B2
Anti-parasitic compounds and uses thereof
Derek Shieh Tan, New York, NY (US); Corinne N. Foley, New York, NY (US); Gustavo Moura-Letts, New York, NY (US); James McKerrow, New York, NY (US); Sivaraman Dandapani, Wakefield, MA (US); Rahul Edwankar, New York, NY (US); Alyssa Verano, New York, NY (US); Debopam Chakrabarti, Winter Springs, FL (US); and Bracken Roberts, Oviedo, FL (US)
Assigned to University of Central Florida Research Foundation, Inc., Orlando, FL (US); The Regents of the University of California, Oakland, CA (US); Memorial Sloan-Kettering Cancer Center, New York, NY (US); and The Broad Institute, Inc., Cambridge, MA (US)
Filed by Memorial Sloan-Kettering Cancer Center, New York, NY (US); The Regents of the University of California, Oakland, CA (US); University of Central Florida Research Foundation, Inc., Orlando, FL (US); and The Broad Institute, Inc., Cambridge, MA (US)
Filed on Nov. 22, 2021, as Appl. No. 17/532,036.
Application 17/532,036 is a continuation of application No. 16/070,137, granted, now 11,180,492, previously published as PCT/US2017/013755, filed on Jan. 17, 2017.
Claims priority of provisional application 62/384,653, filed on Sep. 7, 2016.
Claims priority of provisional application 62/279,401, filed on Jan. 15, 2016.
Prior Publication US 2022/0340557 A1, Oct. 27, 2022
Int. Cl. C07D 471/04 (2006.01); A61P 33/00 (2006.01); A61P 33/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 33/00 (2018.01); A61P 33/06 (2018.01)] 21 Claims
 
1. A compound of Formula (I′):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
n is 1, 2, or 3;
X1 is —CHR4—, —O—, or —S—;
RA1 is —C(═O)R1;
R1 is —N(RA)2;
R2 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3A is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is halogen, hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted imine, substituted or unsubstituted thiocarbonyl group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl,

OG Complex Work Unit Chemistry
RX is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
one instance of RA is hydrogen, and one instance of RA is substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a nitrogen protecting group.